CDK4 and ovarian carcinoma: Twenty-eight of the 102 cancer patients (27.5%) were diagnosed with metastatic prostate cancer and were treated with Androgen Receptor Targeted Agents (ARTAs), 30 patients (29.4%) with metastatic breast cancer under treatment with CDK4/6 inhibitors and 44 (43.1%) with advanced epithelial ovarian cancer that received PARP inhibitors.